



Please complete in typescript, or
in bold black capitals.
CHFP025

88(3)

(Revised 2005)

Particulars of a contract relating to shares allotted as fully or partly paid up otherwise than in cash

Note: This form is only for use where the
contract has not been reduced to writing

Company Number

05510905

Company name in full

NEUROPHARM LIMITED

gives the following particulars of a contract which has not been
reduced to writing

- 1 Class of Shares
(ordinary or preference etc)
- 2 The number of shares allotted as fully
or partly paid up otherwise than in cash
- 3 The nominal value of each such share
- 4a The amount of such nominal value to be
considered as paid up on each share
otherwise than in cash
- b The value of each share allotted
ie. the nominal value and any premium
- c The amount to be considered as paid
up in respect of b

| | | |
|------------|--|--|
| B ORDINARY | | |
| 50 | | |
| £1.00 | | |
| £1.00 | | |
| £1.00 | | |
| £1.00 | | |

continue overleaf

Signed

Date

2.1.07

**Delete as appropriate

** A director / secretary / administrator / administrative receiver / receiver /
official receiver / receiver manager / voluntary arrangement supervisor

Contact Details

You do not have to give any contact
information in the box opposite but if
you do, it will help Companies House to
contact you if there is a query on the
form. The contact information that you
give will be visible to searchers of the

McGrigors LLP

PACIFIC HOUSE, 70 WELLINGTON STREET, GLASGOW, G2 6SB

Tel 0141 248 6677

DX number DX GW 135

DX exchange GLASGOW

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ

DX 33050 Cardiff

for companies registered in England and Wales

or

Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB

DX 235 Edinburgh

for companies registered in Scotland

or LP - 4 Edinburgh 2

THURSDAY



A17

AJLBOLXV

04/01/2007

389

COMPANIES HOUSE

- 5 If the consideration for the allotment of such shares is services, or any consideration other than that mentioned in 6, 7 or 8 below, state the nature and amount of such consideration, and the number of shares allotted

Purchase from Mount Sinai School of Medicine of Orphan Drug Designation, Investigational New Drug application and United States Food and Drug Administration data.

50 B Ordinary shares to be allotted to Mount Sinai School of Medicine in consideration for the data purchased.

- 6 If the allotment is a bonus issue, state the amount of reserves capitalised in respect of this issue

- 7 If the allotment is made in consideration of the release of a debt, e.g., a director's loan account, state the amount released

- 8 If the allotment is made in connection with the conversion of loan stock, state the amount of stock converted in respect of this issue